St Herblain

• HARMONi-3 Not authorised
  2023-504989-37-00 5 Metastatic Squamous Non-small Cell Lung Cancer
• Safety, tolerability, and efficacy of mFOLFIRINOX ±BNT321 as adjuvant therapy following curative resection in patients with pancreatic adeno … Not authorised
  2023-506014-47-00 9 Resected (R0 or R1) pancreatic ductal adenocarcinoma
• A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3 … Pending
  2025-523674-16-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F … Pending
  2025-523675-39-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors … Recruiting
  2023-507485-10-00 9 2026-04-21 advanced breast cancer
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Recruiting
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting
  2023-504445-31-00 4 2024-09-19 Carcinoma, Head and Neck
• A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications Recruiting
  2023-506227-29-00 3 2024-08-30 locally advanced or metastatic solid tumors
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer
• ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc … Recruiting
  2023-505486-92-00 4 2024-02-09 Small bowel adenocarcinoma
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• Anesthetic block of the erector muscles of the lumbar spine to relieve acute lumbar pain: pilot study Recruiting
  2024-511818-21-00 5 2026-03-06 Acute law back pain
• Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting
  2022-502983-19-00 4 2025-07-31 High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
• A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lun … Recruiting
  2023-506539-14-00 3 2025-05-27 Oncology
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub … Recruiting
  2024-510893-25-00 5 2025-04-29 Brain metastases of cancer > brain radionecrosis
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-509787-15-00 5 2025-02-17 Patients with localised prostate cancer and high-risk features of rela
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-507482-26-00 5 2024-10-04 Castrate-resistant prostate cancer with oligometastases on functional
• tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting
  2023-503316-33-00 5 2024-09-26 patients with a positive status for molecular residual disease (MRD) [
• FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage Recruiting
  2024-515118-42-00 11 2024-09-10 Colorectal cancer
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard … Recruiting
  2022-502408-57-00 5 2024-09-04 Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
• Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting
  2023-505298-34-00 4 2024-07-18 Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc

Showing 1–24 of 117 trials